Positive news flow drives valuation uplift
Update | 31 October 2017
Positive news flow drives valuation uplift
Update | 31 October 2017
Share this note
Over the past month Karolinska Development has reported a series of positive outcomes for several of its portfolio companies. The most important in terms of impact on our valuation are the encouraging results from Umecrine Cognition’s Phase Ib study and, to a lesser extent, the successful flotation of BioArctic. A number of further value inflection points, across many of the portfolio companies, are expected over the next 12-18 months. Updating our DCF-based model sees our valuation rise from SEK566m (equivalent to SEK8.92 per share) to SEK1,042m (SEK16.44 per share).
|Adj. PBT (SEKm)||(78.2)||(70.3)||(68.5)||(65.4)|
|Net Income (SEKm)||(1,054.7)||(216.8)||(77.8)||(65.4)|
|Adj. EPS (SEK)||(1.5)||(1.3)||(1.1)||(1.0)|
31 October 2017
|Market Cap (SEKm)||459.7|
|Enterprise Value (SEKm)||628.2|
|Shares in issue||64.3m|
|12 month range||5.25-10.20|
Karolinska Development has been successfully transformed into a leading life sciences investment company that is notably active in the Scandinavian region.
Mick Cooper PhD
+44 (0) 20 3637 5042
+44 20 3637 5041
Karolinska Development continues to make commendable progress across multiple fronts as the portfolio rationalisation and greater commercial focus bear fruit. The past month alone has seen a string of positive outcomes for several the portfolio companies, notably encouraging results in Umecrine Cognition’s Phase Ib clinical trial. Updating for these events, and including Umecrine Cognition within our DCF-based model for the first time, sees our valuation rise from SEK566m (SEK8.92 per share) to SEK1,042m (SEK16.44 per share). The convertible debt and the complexity of the Rosetta Capital dividend split remain an overhang on the shares; nonetheless, we would argue these factors are well documented and already more than discounted in the price.
Karolinska Development is expected to report its results for Q317 on the 31 October. In this Update note we recap the various pieces of news that have been reported by a number of the portfolio companies and have updated our DCF-based valuation model to reflect these. Importantly, the progress seen at Umecrine Cognition means that we include its contribution to the model for the first time. Our updated model sees the valuation rising from SEK566m (SEK8.92 per share) to SEK1,042m (SEK16.44 per share). In line with our philosophy, we continue to employ conservative assumptions throughout; for example, we have not included the additional oesophageal cancer indication for APR-246 within our rNPV for Aprea. Similarly, the earlier stage portfolio companies and retained interests and potential earn-outs should be viewed as possible upside.
In our recent Outlook note (Portfolio companies delivering as planned – September 2017) we detailed how the past two years has seen a revitalisation of the company, with material changes to the investment philosophy, the adoption of a greater commercial outlook, and the creation of a more focussed portfolio. The consequences of these changes have started to show through into the performances of the individual portfolio companies and, importantly, within Karolinska Development itself.
Management’s focus is now firmly on the effective execution of the strategy, with the priority being delivery on critical milestones ahead of potential exits (either through trade sales, IPOs, or licensing deals). Although timings are difficult to predict, the improving visibility suggests that, assuming current progress is maintained, the first major value realisation could happen within the next 12 to 18 months.
The convertible debt and, to a lesser extent, the complexity of the Rosetta Capital dividend split understandably remain as overhangs on the shares. The set-off issue of the convertible bonds saw SEK 67m converted into 10.9m new B shares, which means SEK 384m worth of bonds remain outstanding. The balance sheet is currently sound and has funding in place for the known investment and operational needs, with SEK 189m in cash and equivalents at June 2017. The re-valuation of the portfolio holdings, notably Umecrine Cognition, has strengthened the equity position (allaying a concern we raised in our Outlook note). Nonetheless, we would argue that these issues, although valid, are well documented and more than discounted in the share price.
Aprea Therapeutics is a private Swedish company that is developing novel small molecules targeting the tumour suppressor protein p53 pathways. A Phase II trial of the lead compound, APR-246, in platinum-sensitive high-grade serous ovarian cancer is underway, with the results of this pivotal study expected in 2018. A similar programme examining platinum-resistant ovarian cancer patients is in Phase Ib. A Phase Ib/II trial is also underway in myelodysplastic syndrome, whilst in October the first patient was enrolled in a Phase Ib/II study in oesophageal cancer.
Modus Therapeutics was previously known as Dilaforette until it changed its name in October 2016. Its lead compound, sevuparin, is in Phase II trials in sickle-cell disease. This important study, involving around 150 patients, is expected to produce results in 2018.
OssDsign makes bespoke craniofacial implants, where complicated or difficult cases require individualised implants. The distribution infrastructure has been expanded, with new partnerships in Italy, Spain, Austria, Switzerland, and The Netherlands (adding to those in the UK and Nordic region). Following 510(k) clearance earlier this year to market OSSDSIGN Cranial PSI in the US, a distribution agreement has been signed with Matador Medical Inc.
Promimic has developed a unique coating, known as HAnano Surface, that is used to improve the integration of implants into bones. Commercialisation is now underway, notably in the important US market. Management has been strengthened with Tord Lendau elected Chairman and Magnus Larsson appointed CEO, replacing Ulf Brogren, who relocated to the US to lead the new sales operation in North America.
Dilafor is a drug development company that is developing pharmaceutical products for obstetric indications. Its lead compound is tafoxiparin, which is currently undergoing Phase II studies with first results expected in Q1 2018. A Phase IIb clinical trial with tafoxiparin in women with protracted labour was started in January 2017.
Umecrine Cognition is developing compounds that act on endogenous CNS-active steroids (GABA-steroids). GR3027 is an orally active first-in-class agent that acts to counter the increased GABAA signalling that is believed to cause the clinical symptoms of cognitive and motor function impairment in hepatic encephalopathy (HE). In September 2017 it announced positive Phase Ib data from 18 healthy males at doses ranging from 50 mg once daily to 100 mg twice daily for five days. GR3027 was well tolerated; adverse events were mild and no dose-limiting toxicity was seen. In October 2017 it raised SEK20m to finance an exploratory Phase IIa for GR3027 in idiopathic hypersomnia, a severe orphan disease characterized by excessive daytime sleepiness. These developments have resulted in Karolinska Developments raising the value of its holdings by SEK196m and our including Umecrine Cognition in our valuation model for the first time (see Exhibit 1). This maiden contribution is SEK453m (SEK7.14/share).
Additionally, in October BioArctic was successfully floated on Nasdaq Stockholm. Karolinska Development has a 3.17% holding, which at the time of listing (12th October) was worth SEK48m (updated value is shown in Exhibit 1).
We employ a sum-of-the-parts DCF-based methodology (including rNPV models where appropriate) as we consider this to be the most appropriate way to value Karolinska Development. Importantly, we employ conservative assumptions throughout and only value the key late-stage investments. The inherent value of the other investments in the portfolio and potential earn-outs from previous investments are viewed as additional upside to our valuation. The progress being achieved across the portfolio is reviewed regularly and adjustments made to reflect this.
The main factors driving the uplift in our valuation (as indicated in Exhibit 1) are the first-time inclusion of Umecrine Cognition into our valuation model and the successful flotation of BioArctic on Nasdaq Stockholm. The new valuation is SEK1,042m, or SEK16.44 per share, which compares to our previous valuation of SEK566m, or SEK8.92 per share.
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2017 Trinity Delta Research Limited. All rights reserved.